Publication:


abstract

malondialdehyde (MDA), an end product of lipid peroxidation and biomarker for oxidative stress, and its Soluble receptor (sRAGE) were evaluated in 42 patients with type 1 diabetes mellitus, but without chronic complications, during the early years after diagnosis (0-10 years) and through the further progression of the disease (10-20 and > 20 years after diagnosis). Clinical and biochemical parameters of the cohort of diabetic patients were compared with those determined in 24 healthy individuals. The median levels of MDA in plasma were similar in type 1 diabetes patients and in healthy subjects. In contrast, statistically significant increases were detected in the median values of sRAGE in patients with type 1 diabetes compared with healthy subjects (2423.75 versus 1472.75 pg/ml; p=0.001, Mann-Whitney test). However, no significant between-group differences (p>0.05) were observed in levels of sRAGE when diabetic patients were grouped according to time elapsed after diagnosis. It is concluded that increased plasma levels of sRAGE in type 1 diabetes may provide protection against cell damage and may be sufficient to eliminate excessive circulating MDA during early years after disease onset.

Related Articles
Oxidative stress in families of type 1 diabetic patients.
Diabetes Care. 2000
Oxidative stress in families of type 1 diabetic patients.
Matteucci E, Giampietro O. Diabetes Care. 2000 Aug; 23(8):1182-6.
Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus.
J Pediatr Endocrinol Metab. 2009
Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus.
Dettoraki A, Gil AP, Spiliotis BE. J Pediatr Endocrinol Metab. 2009 Oct; 22(10):895-904.
Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Diabetologia. 2006
Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Diabetologia. 2006 Nov; 49(11):2756-62. Epub 2006 Sep 13.
Review Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Curr Drug Targets. 2007
Review Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S, Matsui T, Nakamura K. Curr Drug Targets. 2007 Oct; 8(10):1138-43.
Review Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker.
Front Biosci (Elite Ed). 2010
Review Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker.
Yamagishi S, Matsui T. Front Biosci (Elite Ed). 2010 Jun 1; 2:1184-95. Epub 2010 Jun 1.